key: cord-0999962-a0catgsk
authors: Grasselli, Giacomo; Zanella, Alberto
title: Critically ill patients with COVID-19 in New York City
date: 2020-05-19
journal: Lancet
DOI: 10.1016/s0140-6736(20)31190-9
sha: 3939e023e911eb0370dbd8a64436f9bec82dac2a
doc_id: 999962
cord_uid: a0catgsk

nan

With more than 4·2 million people infected and over 288 000 deaths as of May 12, 2020, COVID-19 is threatening the entire world, with dramatic consequences for global health and the economy. After the initial outbreaks in China 1 and Italy, 2 the virus rapidly spread worldwide and today the USA is one of the most affected country, with more than 1·3 million cases.

In the absence of effective containment measures, COVID-19 outbreaks are characterised by an overwhelming number of patients requiring hospital admission, which could exceed the capacity even of well organised health-care systems.

Current knowledge of the clinical course of severe forms of COVID-19 is mainly based on retrospective analyses of Chinese, Italian, and US case series. [3] [4] [5] [6] [7] [8] [9] These studies show that critically ill patients with COVID-19 are mainly older, mostly men, and have at least one comorbidity (primarily hypertension), and mortality is very high (ranging from 56% to 97%) when invasive mechanical ventilation is required. However, limited data are available on factors independently associated with mortality. In The Lancet, Matthew Cummings and colleagues 10 ). 203 (79%) patients required invasive mechanical ventilation, median respi ratory system compliance was low (26 mL/cm water), and all patients required a high fraction of inspired oxygen despite having relatively high levels of positive end-expiratory pressure (median 15 cm water). Although obesity might have affected the mechanical properties of the respiratory system, these findings underline that the optimal management of mechanical ventilation in patients with COVID-19 and acute respiratory failure remains poorly understood.

The study by Cummings and colleagues 10 confirms that COVID-19 is characterised by a high incidence of multiple organ dysfunction, as shown by the proportion of patients requiring vasopressors (170 [66%]) and renal replacement therapy (79 [31%]). Regarding pharmacological treatments, antibacterial agents were administered empirically to nearly all critically ill patients (229 [89%]) and hydroxychloroquine was administered to 185 (72%), while corticosteroids and interleukin-6 (IL-6) receptor antagonists were administered to fewer patients (68 [26%] received corticosteroids and 44 [17%] received IL-6 receptor antagonists). No data are available on the temporal changes of inflammatory markers in patients receiving immunomodulating treatments. Furthermore, no information is provided about strategies of anticoagulant therapies, which are particularly interesting given the high incidence of thromboembolic complications associated with COVID-19. 11 With regards to patient outcome, the study conveys important messages. In particular, it shows that the disease is characterised by a high mortality (101 [39%] after a minimum follow-up of 28 days) and prolonged clinical course, as shown by the high percentage of patients still in the hospital (94 [37%]) at the end of follow-up. The multivariable Cox model analysis showed that history of chronic pulmonary disease had the highest adjusted hazard ratio (aHR) for mortality (aHR 2·94 [95% CI 1·48-5·84]). Other independent predictors of death were history of chronic cardiovascular disease (aHR 1·76 [95% CI 1·08-2·86]), older age (aHR 1·31 [95% CI 1·09-1·57]), higher concentrations of IL-6 (aHR 1·11 [95% CI 1·02-1·20] per decile increase), and higher concentrations of D-dimer (aHR 1·10 [95% CI 1·01-1·19] per decile increase) on admission. There appear to be no differences by sex. The association of mortality with higher concentrations of IL-6 and D-dimer is particularly relevant for two reasons. First, it confirms the key pathogenic role played by the activation The study by Cummings and colleagues 10 shows that clinicians can produce high-quality research even when facing an overwhelming clinical workload. However, despite providing important insights, this work leaves us with some unanswered questions. While waiting for the availability of a COVID-19 vaccine, further studies are required to improve and personalise patient treatment, with particular attention to the role of initial non-invasive respiratory support strategies, timing of intubation, optimal setting of mechanical ventilation, and efficacy and safety of immunomodulating agents and anticoagulation strategies. 

who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response

Compliance with triage to intensive care recommendations

COVID-19 in critically ill patients in the Seattle region -case series

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy

Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Clinical course and outcomes of 344 intensive care patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19